
Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Research analysts at HC Wainwright decreased their FY2026 earnings estimates for Merus Labs International in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. He now forecasts that the specialty pharmaceutical company will post earnings of ($2.85) per share for the year, down from their prior estimate of ($2.69). HC Wainwright also issued estimates for Merus Labs International’s Q4 2026 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.70) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.61) EPS, FY2029 earnings at ($1.22) EPS and FY2030 earnings at $1.24 EPS.
Separately, Craig Hallum raised shares of Merus Labs International to a “strong-buy” rating in a research report on Thursday, October 8th. Four analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.
Merus Labs International Stock Performance
Merus Labs International has a 12-month low of C$0.95 and a 12-month high of C$1.76.
About Merus Labs International
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.
Featured Articles
- Five stocks we like better than Merus Labs International
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
